Cargando…

Tolterodine extended release in the treatment of male oab/storage luts: a systematic review

BACKGROUND: Overactive bladder (OAB)/ storage lower urinary tract symptoms (LUTS) have a high prevalence affecting up to 90% of men over 80 years. The role of sufficient therapies appears crucial. In the present review, we analyzed the mechanism of action of tolterodine extended-release (ER) with th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gacci, Mauro, Novara, Giacomo, De Nunzio, Cosimo, Tubaro, Andrea, Schiavina, Riccardo, Brunocilla, Eugenio, Sebastianelli, Arcangelo, Salvi, Matteo, Oelke, Matthias, Gravas, Stavros, Carini, Marco, Serni, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4230346/ https://www.ncbi.nlm.nih.gov/pubmed/25348235 http://dx.doi.org/10.1186/1471-2490-14-84

Ejemplares similares

PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH
por: Gacci, M., et al.
Publicado: (2013)

Tadalafil Alone or in Combination with Tamsulosin for the Management for LUTS/BPH and ED
por: Sebastianelli, A., et al.
Publicado: (2020)

The use of a novel smartphone app for monitoring male luts treatment during the COVID-19 outbreak
por: Morselli, Simone, et al.
Publicado: (2020)

Quality of Life and Sexual Health in the Aging of PCa Survivors
por: Gacci, Mauro, et al.
Publicado: (2014)

Corrigendum to “Quality of Life and Sexual Health in the Aging of PCa Survivors”
por: Gacci, Mauro, et al.
Publicado: (2015)

Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study
por: Gacci, Mauro, et al.
Publicado: (2017)

Tadalafil 5 mg Alone or in Combination with Tamsulosin 0.4 mg for the Management of Men with Lower Urinary Tract Symptoms and Erectile Dysfunction: Results of a Prospective Observational Trial
por: Sebastianelli, Arcangelo, et al.
Publicado: (2019)

The Role of Combination Therapy with α-Blockers and Hexanic Extract of Serenoa repens in the Treatment of LUTS/BPH
por: De Nunzio, Cosimo, et al.
Publicado: (2022)

The Investigative Role of Statins in Ameliorating Lower Urinary Tract Symptoms (LUTS): A Systematic Review
por: Russo, Giorgio Ivan, et al.
Publicado: (2021)

The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction
por: Gacci, Mauro, et al.
Publicado: (2013)

Translation and validation of the Italian version of the user version of the Mobile Application Rating Scale (uMARS)
por: MORSELLI, SIMONE, et al.
Publicado: (2021)

Latest Evidence on Post-Prostatectomy Urinary Incontinence
por: Gacci, Mauro, et al.
Publicado: (2023)

Tolterodine extended release is well tolerated in older subjects
por: Griebling, T L, et al.
Publicado: (2009)

Update on tolterodine extended-release for treatment of overactive bladder
por: Omotosho, Tola, et al.
Publicado: (2010)

Sodium hyaluronate and chondroitin sulfate replenishment therapy can improve nocturia in men with post-radiation cystitis: results of a prospective pilot study
por: Gacci, Mauro, et al.
Publicado: (2015)

Obesity and Prostate Cancer: The Tip of a High Mountain Still to Be Conquered
por: Nunzio, Cosimo De, et al.
Publicado: (2020)

The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly
por: Ulahannan, Danny, et al.
Publicado: (2009)

Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society
por: Oelke, Matthias, et al.
Publicado: (2010)

Current status of 5α-reductase inhibitors in the management of lower urinary tract symptoms and BPH
por: Gravas, Stavros, et al.
Publicado: (2009)

LUTS/BPH and SARS-COV2: when a misunderstanding in the correct physiopathology results in incorrect associations
por: De Nunzio, Cosimo, et al.
Publicado: (2021)

Proctored Step by Step Training Program for GreenLight Laser Anatomic Photovaporization of the Prostate: A Single Surgeon's Experience
por: Sessa, Francesco, et al.
Publicado: (2021)

Patient’s adherence on pharmacological therapy for benign prostatic hyperplasia (BPH)-associated lower urinary tract symptoms (LUTS) is different: is combination therapy better than monotherapy?
por: Cindolo, Luca, et al.
Publicado: (2015)

The effect of extended release tolterodine used for overactive bladder treatment on female sexual function
por: Zachariou, Athanasios, et al.
Publicado: (2017)

Efficacy of tolterodine in children with overactive bladder
por: Koç, Başak, et al.
Publicado: (2020)

Inflammation and Prostate Cancer: Pathological Analysis from Pros-IT CNR 2
por: Sessa, Francesco, et al.
Publicado: (2023)

The role of COVID-19 in prostate tissue inflammation: first pathological evidence
por: Pecoraro, Alessio, et al.
Publicado: (2022)

Robotic Kidney Transplantation from a Brain-Dead Deceased Donor in a Patient with Autosomal Dominant Polycystic Kidney Disease: First Case Report
por: Vignolini, Graziano, et al.
Publicado: (2018)

Cost Effectiveness of Mirabegron Compared with Tolterodine Extended Release for the Treatment of Adults with Overactive Bladder in the United Kingdom
por: Aballéa, Samuel, et al.
Publicado: (2014)

Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia
por: De Nunzio, Cosimo, et al.
Publicado: (2017)

The role of prostate-specific antigen density in men with low-risk prostate cancer suitable for active surveillance: results of a prospective observational study
por: Sebastianelli, Arcangelo, et al.
Publicado: (2019)

Plain language summary: does treatment with vibegron result in improvements in overactive bladder (OAB) symptoms that are meaningful to people with OAB?
por: Frankel, Jeffrey, et al.
Publicado: (2023)

On the Absolute Stereochemistry of Tolterodine: A Circular Dichroism Study
por: Górecki, Marcin, et al.
Publicado: (2019)

Comparison of Tumor Seeding and Recurrence Rate After Laparoscopic vs. Open Nephroureterectomy for Upper Urinary Tract Transitional Cell Carcinoma
por: Morselli, Simone, et al.
Publicado: (2021)

Physical Inactivity, Metabolic Syndrome and Prostate Cancer Diagnosis: Development of a Predicting Nomogram
por: De Nunzio, Cosimo, et al.
Publicado: (2023)

AB33. Botox: the novel therapy for OAB
por: Deng, Donna
Publicado: (2014)

Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder
por: Rajabalaya, Rajan, et al.
Publicado: (2016)

Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study
por: Oelke, Matthias, et al.
Publicado: (2011)

Urine Proteomic Study in OAB Patients—Preliminary Report
por: Futyma, Konrad, et al.
Publicado: (2020)

The emperor has no clothes: OAB can be cured surgically
por: Petros, Peter
Publicado: (2022)

Improvement of quality of life and symptom burden after robot-assisted radical prostatectomy in patients with moderate to severe LUTS
por: Leyh-Bannurah, Sami-Ramzi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_35eebf3c35v9h82kvgsq39faq3